Aktuellt
SENASTE
Redeye comments on Spago announcing full recruitment of the second dosing cohort of its phase I SPAGOPIX-01 trial with contrast agent SN132D in breast cancer. We are encouraged by today's news following unfortunate COVID-related delays for SPAGOPIX-01. The company expects interim result publication in early 2022, and we look forward to analyzing data from the second cohort at that point.
LÄS MER
